Aimmune Therapeutics (AIMT)

[crudeoil24]

Aimmune Therapeutics Share Up After DBV Withdraws FDA Application
7:27 pm ET December 19, 2018 (Dow Jones) Print
By Josh Beckerman

Aimmune Therapeutics Inc. (AIMT) shares were recently up 10.8% to $24.05 after hours. Another company focused on food allergy treatments, DBV Technologies SA (DBVT, DBV.FR), said it withdrew an application with the U.S. Food and Drug Administration for its Viaskin Peanut patch.

On Wednesday morning, Aimmune said it started a Phase 3 trial of AR101 in peanut-allergic children from one to three years old. During the regular session, Aimmune shares fell 1.2%.

Aimmune received a $98 million investment from Nestle SA's (NESN.EB) Nestle Health Science in November.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

December 19, 2018 19:27 ET (00:27 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.